Does matched unrelated donor transplantation have the same outcome as matched sibling transplantation in unselected patients?
Best Pract Res Clin Haematol., Dec;25(4):483-6 (2012)
Peripheral-blood stem cells versus bone marrow from unrelated donors.
N. Engl. J. Med., Oct;367(16):1487-96 (2012)
Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transpl
J. Clin. Oncol., Sep;30(26):3194-201 (2012)
MHC-resident variation affects risks after unrelated donor hematopoietic cell transplantation.
Sci Transl Med., Jul;4(144):144ra101 (2012)
Effect of HLA-Matching Recipients to Donor Noninherited Maternal Antigens on Outcomes after Mismatched Umbilical Cord Blood Transplantation for Hematologic Malignancy.
Biol. Blood Marrow Transplant., Dec;18(12):1890-6 (2012)
Allogeneic hematopoietic stem cell donation: standardized assessment of donor outcome data-A WBMT consensus document.
Bone Marrow Transplant., Jul (2012)
Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning.
Biol. Blood Marrow Transplant., Nov;18(11):1727-33 (2012)
Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research.
Biol. Blood Marrow Transplant., Oct;18(10):1471-8 (2012)
A perspective on the selection of unrelated donors and cord blood units for transplantation.
Blood., Jul;120(2):259-65 (2012)
Lenalidomide after stem-cell transplantation for multiple myeloma.
N. Engl. J. Med., May;366(19):1770-81 (2012)
Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.
Biol. Blood Marrow Transplant., Jul;18(7):1007-11 (2012)
Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia.
Biol. Blood Marrow Transplant., Sep;18(9):1446-54 (2012)
Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study.
Lancet Oncol., Apr;13(4):366-74 (2012)
Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia.
Blood., Apr;119(17):3908-16 (2012)
Outcomes of allogeneic hematopoietic cell transplantation for adolescent and young adults compared with children and older adults with acute myeloid leukemia.
Biol. Blood Marrow Transplant., Jun;18(6):861-73 (2012)
Risk factors for acute GVHD and survival after hematopoietic cell transplantation.
Blood., Jan;119(1):296-307 (2012)
Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis.
Bone Marrow Transplant., Jun;47(6):810-6 (2012)
Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis.
Lancet Oncol., Dec;12(13):1214-21 (2011)
Easy-to-read informed consent forms for hematopoietic cell transplantation clinical trials.
Biol. Blood Marrow Transplant., Feb;18(2):183-9 (2012)
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.
Lancet Oncol., Dec;12(13):1195-203 (2011)